1. Home
  2. FWRG vs PHAR Comparison

FWRG vs PHAR Comparison

Compare FWRG & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Watch Restaurant Group Inc.

FWRG

First Watch Restaurant Group Inc.

N/A

Current Price

$10.23

Market Cap

768.7M

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$9.95

Market Cap

793.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FWRG
PHAR
Founded
1983
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
768.7M
793.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FWRG
PHAR
Price
$10.23
$9.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
2
Target Price
$19.50
★ $34.35
AVG Volume (30 Days)
★ 1.0M
32.7K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3.33
N/A
EPS
N/A
★ N/A
Revenue
★ $1,222,501,000.00
N/A
Revenue This Year
$13.60
$1.92
Revenue Next Year
$11.67
$8.85
P/E Ratio
★ N/A
$3,041.22
Revenue Growth
★ 20.34
N/A
52 Week Low
$9.88
$9.62
52 Week High
$18.82
$21.34

Technical Indicators

Market Signals
Indicator
FWRG
PHAR
Relative Strength Index (RSI) 35.18 38.55
Support Level $10.03 $9.62
Resistance Level $13.47 $11.60
Average True Range (ATR) 0.42 0.40
MACD 0.02 -0.05
Stochastic Oscillator 18.45 7.95

Price Performance

Historical Comparison
FWRG
PHAR

About FWRG First Watch Restaurant Group Inc.

First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. The company generates revenues from Restaurant sales and Franchise revenues. It generates maximum revenue from Restaurant sales.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: